EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY-NC 4.0

Pembrolizumab plus chemotherapy with or without bevacizumab in East Asian participants with persistent, recurrent, or metastatic cervical cancer: results from KEYNOTE-826 final analysis

Yong-Man Kim iD, Shin Nishio iD, Se Ik Kim iD, Kosei Hasegawa iD, Coraline Dubot iD, M Valeria Cáceres iD, Krishnansu S Tewari iD, Domenica Lorusso iD, Jeong-Won Lee iD, Wen-Shiung Liou iD, Kan Li iD, Cumhur Tekin iD und 2 weitere

Journal of Gynecologic Oncology · 2025

DOI: 10.3802/jgo.2025.36.e110 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Gynecologic Oncology, 2025. Verfasst von Yong-Man Kim und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan, Seoul, Korea. ymkim@amc.seoul.kr. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Merck & Co., Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: In the phase 3 KEYNOTE-826 study (NCT03635567), pembrolizumab plus chemotherapy with or without bevacizumab significantly improved progression-free survival (PFS) and overall survival (OS) in participants with persistent, recurrent, or metastatic cervical cancer. We report an exploratory analysis of outcomes for participants enrolled in East Asia based on the final analysis of KEYNOTE-826. METHODS: Participants were randomized 1:1 to receive pembrolizumab 200 mg or placebo every 3 weeks for up to 35 cycles. All participants received chemotherapy with paclitaxel and cisplatin or carboplatin for up to 6 cycles, and optionally received bevacizumab at the investigator's discretion. PFS and OS were dual primary endpoints. RESULTS: Ninety-seven participants from East Asia were enrolled in the intention-to-treat population. At data cutoff (October 3, 2022), in the intention-to-treat population, median PFS in the pembrolizumab plus chemotherapy and placebo plus chemotherapy groups was 18.0 and 10.4 months, respectively (hazard ratio [HR]=0.42; 95% confidence interval [CI]=0.23-0.77); median OS was not reached and 20.4 months, respectively (HR=0.53; 95% CI=0.28-0.99). In the programmed cell death ligand 1 combined positive score (CPS) ≥1 population, median PFS was 29.3 and 10.9 months, respectively (HR=0.36; 95% CI=0.19-0.68); median OS was not reached and 17.4 months, respectively (HR=0.43; 95% CI=0.22-0.86). The most common adverse events with pembrolizumab plus chemotherapy versus placebo plus chemotherapy were alopecia (75% vs. 68%) and anemia (67% vs. 65%). CONCLUSION: These data support the use of pembrolizumab plus chemotherapy with or without bevacizumab for the treatment of persistent, recurrent, or metastatic cervical cancer in East Asian patients. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03635567.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabNeoplasm Recurrence, LocalUterine Cervical NeoplasmsAdultAgedFemaleHumansMiddle AgedCarboplatinCisplatinEast Asian PeoplePaclitaxelProgression-Free Survival

Stichwörter der Autor:innen

Cervical CancerEast AsiaPembrolizumab

Substanzen

Antibodies, Monoclonal, HumanizedBevacizumabCarboplatinCisplatinPaclitaxelpembrolizumab

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan, Seoul, Korea. ymkim@amc.seoul.kr.
  • Kurume University School of Medicine, Kurume, Japan.
  • Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea.
  • Saitama Medical University International Medical Center, Hidaka, Japan.
  • Institut Curie Saint-Cloud, Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens, Saint-Cloud, France.
  • Instituto de Oncología Ángel H. Roffo, Buenos Aires, Argentina.

ORCID-Profile: Yong-Man Kim, Shin Nishio, Se Ik Kim, Kosei Hasegawa, Coraline Dubot, M Valeria Cáceres, Krishnansu S Tewari, Domenica Lorusso, Jeong-Won Lee, Wen-Shiung Liou, Kan Li, Cumhur Tekin, Nicoletta Colombo, Bradley J Monk

Förderung

  • Merck & Co., Inc.

Zitieren

APA

Kim, Y. M., Nishio, S., Kim, S. I., Hasegawa, K., Dubot, C., Cáceres, M. V., Tewari, K. S., Lorusso, D., Lee, J. W., Liou, W. S., Li, K., Tekin, C., Colombo, N., & Monk, B. J. (2025). Pembrolizumab plus chemotherapy with or without bevacizumab in East Asian participants with persistent, recurrent, or metastatic cervical cancer: results from KEYNOTE-826 final analysis. Journal of Gynecologic Oncology. https://doi.org/10.3802/jgo.2025.36.e110

Vancouver

Kim YM, Nishio S, Kim SI, Hasegawa K, Dubot C, Cáceres MV, et al. Pembrolizumab plus chemotherapy with or without bevacizumab in East Asian participants with persistent, recurrent, or metastatic cervical cancer: results from KEYNOTE-826 final analysis. Journal of Gynecologic Oncology. 2025. doi:10.3802/jgo.2025.36.e110

BibTeX
@article{Kim2025,
  author = {Kim, Yong-Man and Nishio, Shin and Kim, Se Ik and Hasegawa, Kosei and Dubot, Coraline and Cáceres, M Valeria and Tewari, Krishnansu S and Lorusso, Domenica and Lee, Jeong-Won and Liou, Wen-Shiung and Li, Kan and Tekin, Cumhur and Colombo, Nicoletta and Monk, Bradley J},
  title = {Pembrolizumab plus chemotherapy with or without bevacizumab in East Asian participants with persistent, recurrent, or metastatic cervical cancer: results from KEYNOTE-826 final analysis},
  journal = {Journal of Gynecologic Oncology},
  year = {2025},
  doi = {10.3802/jgo.2025.36.e110}
}
Kostenlos starten →